| Similar Articles |
|---|
 |
IEEE Spectrum
February 2006
Samuel K. Moore |
Ajay Royyuru: Genographer In our genes: How this computational biologist traces the history of human migration through DNA data.   |
Bio-IT World
March 17, 2004 |
Signs of Spring Colin Hill, CEO of Gene Network Sciences, a predictive systems biology company, says the worst is behind the bio-IT industry. "The hype has dissipated, and companies are focused on delivering the results," he says. Hill's strategy includes developing additional products, which should generate near-term revenue. |
Bio-IT World
September 2006
John Russell |
IBM Races H5N1 Unlike most (perhaps all) of its IT brethren, IBM has the size and breadth of technology expertise to make waves in basic research beyond IT and to tackle global projects that enable Big Blue to do well by doing good. The Global Pandemic Initiative is a perfect example of that capacity. |
Bio-IT World
May 9, 2003
Michael Greeley |
Mechanistic Models Investors are backing predictive modeling software that could speed drug development. |
Bio-IT World
September 9, 2002 |
Letters Frustrated in Gene Town... IT for the Biologists, by the Biologists?... |
Bio-IT World
October 9, 2002
Debra Goldfarb |
A Study in Contrasts Recently, IDC conducted a pair of focus groups as part of a broader study on technology adoption across bio-IT workloads. |
Bio-IT World
October 14, 2004
Michael Greeley |
Go East Business is great in China, and the government is strongly encouraging the local biotech industry. |
Bio-IT World
May 2006
Kevin Davies |
Microsoft's 2020 Vision for Science The Microsoft Research report Towards 2020 is considered the first report to articulate a comprehensive vision of science towards 2020, particularly the impact of the convergence of computer science and the other sciences. |
Bio-IT World
April 15, 2003
Michael Greeley |
Bio Battles Upstream As biotech business models evolve, the question remains: Which will survive? |
Bio-IT World
Dec 2005/Jan 2006
Michael A. Greeley |
Infinite Demand for the Unavailable The bio-IT field is once again attracting venture capital, but at a more moderate, deliberate pace than the euphoria of the late 1990s. |
Bio-IT World
June 2006
Michael A. Greeley |
Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process. |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
Bio-IT World
September 11, 2003 |
Show Me the Evidence ... Some emerging bio-IT services companies are beginning to attract venture capital. |
Bio-IT World
June 12, 2002
Beth Schachter |
Informatics Moves to the Head of the Class The race is on to increase the quantity and quality of bio-IT training programs as government and academia bet the need will be great. Will the job market back up that bet? |
Bio-IT World
January 13, 2003
Michael Greeley |
What Do We Do Now? Like it or not, the supply of capital is an important ingredient in the continued development of the bio-IT industry. Appreciating and understanding the forces currently at work in the VC marketplace can only help in raising capital. |
Bio-IT World
July 2005
Michael A. Greeley |
CEO Lessons on Product and Market In the face of extraordinary R&D budgets generated by biopharma industries, bio-IT companies must refine their value propositions in the hopes that meaningful (predictable and repeatable) revenue streams can be created. |
Bio-IT World
June 12, 2002
Morris R. Levitt |
A New Economic Paradigm for Bio-IT? All who work in the bio-IT industry -- scientists, IT and informatics managers, and executives -- have been aware for some time that we seem to be suspended between an acute sense of crisis and a field of boundless opportunity. |
Bio-IT World
March 10, 2003 |
Champions of the Bio-IT World PART II Senior executives from bioinformatics and biotech companies talk about the goals, philosophies, and products that each organization brings to the bio-IT table. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
